Oxford University Press's
Academic Insights for the Thinking World

  • Author: Caroline Robert

Gut microbiota and melanoma treatment responses

Monoclonal antibodies directed against checkpoint molecules such as CTLA-4 have recently demonstrated success in cancer immunotherapy in patients with melanoma. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a T cell receptor that functions as an immune checkpoint, downregulating immune responses. The monoclonal antibody, ipilimumab, blocks CTLA-4 by inhibiting this negative immune signal and amplifying immune responses.

Read More